ATTENTION Altimmune, Inc. (ALT) Investors: Possible Fraud – Contact Levi & Korsinsky Today
NEW YORK, NY / ACCESS Newswire / July 1, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Altimmune, Inc. ("Altimmune, Inc.") (NASDAQ:ALT) concerning possible violations of federal securities laws. Altimmune announced topline results from the IMPACT Phase 2b trial of pemvidutide in metabolic dysfunction-associated steatohepatitis (MASH), revealing that the […]